Obesity influences the thresholds, but even in nonobese patients with dyspnea, optimal cutoffs may be lower than recommended.

A maladaptive stress response might be amenable to behavioral or other interventions to lower future CV risk, say researchers ...

Task force members say that continued collection of data will help build credibility of what is “fair market value” for ...

This year’s report shows risk factors on the rise, enduring racial and geographic gaps, and clues to the global picture, too.

These latest data reinforce years of smaller studies, but whether they should change practice is a matter of debate.

The ability to diagnose MI was better with troponin I, but T better predicted mortality. Both tests have strengths, ...

New data from US centers suggest some overtesting in patients without chest pain, and undertesting in those who do.

It’s not yet time to abandon seated BP measurements, but taking a look at supine readings may provide enhanced risk ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Much has changed since the 2013 document came out, with new information on pacing devices, techniques, and more.

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

After guideline changes, aspirin use dropped off overall, even for higher-risk patients in whom it might still be considered.